BioSpace News Archive

BioLineRx Ltd. reported its unaudited financial results for the second quarter ended June 30, 2023, and provided corporate and portfolio updates.

OKYO Pharma Limited is pleased to announce that it has enrolled and randomized 90% of the patients in its 240-patient Phase 2 multi-center, double-masked, placebo-controlled clinical trial of topical ocular OK-101 to treat DED.

Ionis Pharmaceuticals, Inc. announced that management will participate in fireside chats at the following investor conferences.

REGENXBIO Inc. announced that initial interim data from a first-in-human single-patient, investigator-initiated trial of RGX-181 for the treatment of late-infantile neuronal ceroid lipofuscinosis type 2 disease, a form of Batten disease, were presented at the Society for the Study of Inborn Errors of Metabolism Annual Symposium in Jerusalem.

Zealand Pharma announces designation of priority review by the US FDA for dasiglucagon in congenital hyperinsulinism.

IRLAB Therapeutics AB, a company discovering and developing novel treatments for Parkinson’s disease, announced that the company’s interim report for the period January-June 2023, has been published.

Asieris Pharmaceuticals announced that the National Medical Products Administration has approved the Investigational Drug application for its oral drug APL-1401 for the treatment of moderately-to-severely active ulcerative colitis.The IND application had previously been approved by the U.S. Food and Drug Administration.

BioInvent International “In the quarter, we had impressive early signals of efficacy in the Phase 1/2 trial of our lead drug candidate, the novel anti-FcgRIIB antibody BI-1206, in combination with rituximab in non-Hodgkin’s lymphoma.

SOPHiA GENETICS announced that CHU Bordeaux, a full-service hospital servicing the population of Bordeaux and the surrounding area, has completed implementation of the SOPHiA DDM™ Platform into its organization.

Oculis Holding AG announced that Riad Sherif, MD, Chief Executive Officer, and Sylvia Cheung, Chief Financial Officer will be attending and presenting at the following upcoming investor conferences: